再次冠状动脉旁路移植术的20年结局与扩大介入治疗的考量
该研究回顾性分析了1993年至2014年间单中心748例再次CABG患者,中位随访15.1年。结果显示早期死亡率6%,1年、5年、10年生存率分别为89%、77%、51%,年龄、糖尿病、外周血管疾病和终末期肾病透析与远期死亡风险增加相关。
要点
- 再次CABG早期死亡率6%,1年、5年、10年生存率分别为89%、77%、51%。
- 终末期肾病透析患者远期死亡风险显著升高(HR 11.85)。
- 年龄、糖尿病、外周血管疾病是远期死亡的独立预测因素。
核心结论
- 再次CABG可安全实施,早期和远期并发症及死亡率较低。
- 年龄、糖尿病、肾脏疾病和外周血管疾病是远期死亡率的重要预测因素,应指导治疗策略选择。
研究设计与样本
- 回顾性单中心队列研究,纳入1993年1月至2014年6月748例再次CABG患者。
- 中位年龄69岁(范围36至88),男性644例(86%),中位随访15.1年,随访完整率100%。
主要发现
- 术前合并症:糖尿病191例(26%),高血压562例(75%),外周血管病206例(28%),脑血管病史121例(16%),既往心肌梗死459例(61%)。
- 既往CABG次数:1次682例(91%),2次62例(8%),3次4例(1%)。
- 全部手术在体外循环下完成,中位体外循环时间95分钟(最大378),中位阻断时间48分钟(最大176)。
- 早期死亡47例(6%),非致死性并发症:肾衰竭51例(7%),卒中15例(2%),肺炎22例(3%)。
- 远期死亡危险因素:年龄(HR 1.74,p<0.001)、糖尿病(HR 1.51,p<0.001)、外周血管病(HR 1.51,p<0.001)、终末期肾病透析(HR 11.85,p<0.001);左室射血分数每增加10%保护性HR 0.78(p<0.001)。
临床怎么用
- 再次CABG术前应评估年龄、糖尿病、外周血管疾病和肾功能,以识别高危患者并个体化选择治疗策略。
局限性
- 单中心回顾性研究,数据来自历史队列,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Owing to an inevitable degeneration of grafts over time, patients may require consideration for repeat coronary artery bypass graft (CABG) surgery. As our understanding of preoperative risks associated with redo CABG surgery is limited and availability of data is limited to historical cohorts, we sought to evaluate our contemporary 20-year experience with this challenging patient population. METHODS: Between January 1993 and June 2014, 748 patients underwent redo CABG surgery at our institution. Median age at reoperation was 69 years (range, 36 to 88), and 644 (86%) were male. Median follow-up was 15.1 years and was 100% complete. Preoperatively, 191 patients (26%) had diabetes mellitus, 562 (75%) had hypertension, 206 (28%) had peripheral vascular disease with 121 (16%) having a history of cerebrovascular disease, and 459 (61%) had prior myocardial infarction. Number of prior CABG operations was 1 in 682 patients (91%), 2 in 62 patients (8%), and 3 in 4 patients (1%). RESULTS: All patients underwent isolated redo CABG surgery; all 748 (100%) procedures were performed using cardiopulmonary bypass, with median time on pump of 95 minutes (maximum, 378) and cross-clamp time of 48 minutes (maximum, 176). There were 47 early deaths (6%); early nonfatal morbidity included renal failure in 51 patients (7%), stroke in 15 (2%), and pneumonia in 22 (3%). Overall 1-, 5-, and 10-year survival was 89%, 77%, and 51%, respectively. Age (hazard ratio [HR] 1.74, p < 0.001), diabetes (HR 1.51, p < 0.001), peripheral vascular disease (HR 1.51, p < 0.001), and end-stage renal disease with dialysis (HR 11.85, p < 0.001) were associated with increased long-term mortality, whereas higher left ventricular ejection fraction (per 10% increase) was protective (HR 0.78, p < 0.001). CONCLUSIONS: Redo CABG can be performed safely with low early and late morbidity and mortality. Important predictors of long-term mortality such as age, diabetes, renal disease, and peripheral vascular disease were identified and should guide the treatment strategy chosen for this challenging group of patients.
引用
- Maltais S, Widmer RJ, Bell MR, et al. Reoperation for Coronary Artery Bypass Grafting Surgery: Outcomes and Considerations for Expanding Interventional Procedures. Ann Thorac Surg. 2016. PMID: 28012643. doi:10.1016/j.athoracsur.2016.09.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。